Business Description
Avadel Pharmaceuticals PLC
NAICS : 325414
SIC : 2834
ISIN : IE00BDGMC594
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 40.06 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 4.1 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -5 | |||||
3-Year EPS without NRI Growth Rate | -63.8 | |||||
3-Year FCF Growth Rate | -21.7 | |||||
3-Year Book Growth Rate | -29.4 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 60.28 | |||||
9-Day RSI | 60.15 | |||||
14-Day RSI | 59.8 | |||||
6-1 Month Momentum % | 67.42 | |||||
12-1 Month Momentum % | 61.75 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.64 | |||||
Quick Ratio | 3.36 | |||||
Cash Ratio | 2.85 | |||||
Days Inventory | 2459.94 | |||||
Days Sales Outstanding | 87.53 | |||||
Days Payable | 4693.66 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.4 | |||||
Shareholder Yield % | -3.06 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 96.98 | |||||
Operating Margin % | -492.97 | |||||
Net Margin % | -573.17 | |||||
FCF Margin % | -459.58 | |||||
ROE % | -284.41 | |||||
ROA % | -95.14 | |||||
ROIC % | -211.06 | |||||
ROC (Joel Greenblatt) % | -1173.85 | |||||
ROCE % | -133.59 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 56.87 | |||||
PB Ratio | 18.17 | |||||
Price-to-Tangible-Book | 22.54 | |||||
EV-to-EBIT | -10.02 | |||||
EV-to-Forward-EBIT | 96.6 | |||||
EV-to-EBITDA | -10.14 | |||||
EV-to-Forward-EBITDA | 1211.26 | |||||
EV-to-Revenue | 54.06 | |||||
EV-to-Forward-Revenue | 9.01 | |||||
EV-to-FCF | -11.76 | |||||
Price-to-Net-Current-Asset-Value | 27.83 | |||||
Price-to-Net-Cash | 57.45 | |||||
Earnings Yield (Greenblatt) % | -9.98 | |||||
FCF Yield % | -7.97 |